- Market Capitalization, $K 1,762,297
- Shares Outstanding, K 69,601
- Annual Sales, $ 257,650 K
- Annual Income, $ -128,150 K
- 60-Month Beta 1.43
- Price/Sales 6.86
- Price/Cash Flow N/A
- Price/Book 321.59
|Period||Period Low||Period High||Performance|
| || |
+1.84 (+8.06%)since 05/24/19
| || |
+4.99 (+25.36%)since 03/22/19
| || |
+8.60 (+53.52%)since 06/22/18
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a nationwide registry study for kidney transplant recipients called ProActive. This is one of the largest known prospective...
Investors in Natera Inc saw new options begin trading this week, for the January 2020 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value,...
OncoCyte (OCX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
We looked at the Biotechnology industry and measured relative performance to find the top stocks. Relative outperformance is a bullish sign of underlying fundamental and technical strength. We look at...
SmarTrend identified an Uptrend for Natera Inc (NASDAQ:NTRA) on February 11th, 2019 at $14.87. In approximately 3 months, Natera Inc has returned 54.47% as of today's recent price of $22.97.
Natera Inc (NASDAQ:NTRA) traded in a range yesterday that spanned from a low of $21.15 to a high of $22.77. Yesterday, the shares gained 7.2%, which took the trading range above the 3-day high of $21.87...
Natera (NTRA) delivered earnings and revenue surprises of 8.47% and 0.63%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
SAN CARLOS, Calif. (AP) _ Natera Inc. (NTRA) on Thursday reported a loss of $34.1 million in its first quarter.
Natera, Inc. (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of circulating cell-free DNA, today reported financial results for the first quarter ended March 31, 2019 and provided...
A new clinical study shows that Natera's Signatera(TM) test identified colorectal cancer recurrence up to 16.5 months earlier than radiologic imaging by detecting traces of tumor DNA in the blood after...